Artificial Intelligence in Life Sciences: Cost-Benefit of Implementation and Avoiding Common Pitfalls
Mini Symposium: Monday, 12 October 2020 (12:30 – 17:00)


Overview:
Recent developments have confirmed that Artificial Intelligence (AI) and Machine Learning (ML) has the potential to reshape the life sciences sector. Whether the ultimate driver is cost efficiency, optimizing clinical trial design and execution, or potentially accelerating speed to market, AI technology can enable a true competitive edge by potentially achieving all three.

By attending this symposium, Innoplexus will demystify AI & ML, explore its potential, alleviate concerns and set realistic expectations about what this powerful technology can do.

12:30: Agenda for the Pre workshop / Symposium day:
Registration, snacks, coffee, light meet & greet

13:00: Introductions & Icebreaker:
This session is designed to get to know one another and share AI-related insights, concerns and challenges. The information will be documented, and we will aim to address these during the course of the day.

13.30 SESSION 1 –  The Potential of Artificial Intelligence / Machine Learning in Life Sciences
Presented by Gunjan Bhardwaj, CEO & Founder, Innoplexus

About Gunjan:
Gunjan Bhardwaj is the Founder and CEO of the Innoplexus group. He was earlier with the Boston Consulting Group and before that the leader of the global business performance think-tank of Ernst & Young and a manager in the German practice with a solution focus on strategy and innovation.He has led projects in strategy, analytics, and technology for various clients in different parts of the world. Gunjan was also a partner, senior-editor, and advisor for a prominent online innovation management journal and was a member of the scientific advisory board of a US based not for profit institute researching in complexity sciences in the healthcare industry.

14:15: Q&A, Discussion

14:30: Refreshment break

14:40 SESSION 2
How Innoplexus’ platforms can help at various stages of drug lifecycle and setting realistic expectations about what AI can do
Presented by Rita Kelley, Managing Director, US Operations, Innoplexus

About Rita:
Rita Kelley is the Managing Director of Innoplexus USA and Senior Vice President of Corporate Development & Marketing at Innoplexus. She has more than 30 years of experience in driving successful commercialization from R&D to the business organization. Prior to joining Innoplexus, Rita served as Vice President of Medical and Commercial Strategy at BioNTech SE, where she helped build and significantly grow the novel mRNA immunotherapy pipeline in cancer and rare diseases.Rita also has held senior executive global positions at Pfizer, Novartis, and Merck, where she led the global effort that successfully achieved the historic, first in class, best in class approval of Keytruda® for treating MSI-H cancers, regardless of biology, gaining approval in 22 indications. She has also successfully launched five products globally which have achieved over USD 1B in sales. Through these efforts, she has excelled in bringing new drugs to market and significantly increased business revenues through the identification of new pathways across multiple indications.

15:25: Q&A, Discussion

15.40: Refreshment break

15:50 SESSION 3 INTERACTIVE WORKSHOP:
Barriers to implementing Artificial Intelligence / Machine Learning initiatives at your organization & identifying possible ssolutions
How will the interactive session work?

  • Within this session, you will form working groups and complete a case study assignment. This will allow you to share your challenges and objectives with your peers and work collaboratively to solve the problems. You will share your outcomes with fellow attendees, all of which will be memorialized.
  • Key focus areas include:
    • 1. What are your/colleagues concerns regarding AI initiatives rolling out at your organization? What can be done to overcome these?
    • 2. What other implementation barriers need to be overcome; who & how many decision-makers are involved in implementation?
    • 3. In which areas of drug discovery & development do you think that AI solutions can most assist you?

Facilitated by George Tsiolis, Head of Global Marketing, Innoplexus

4.45: Wrap up